Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study

(2012) I.-M. Chen et al.   BLOOD

High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations

(2012) M. W. M. Kuhn et al.   BLOOD

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Gene mutation and AML pathogenesis

(2011) H. Dombret   BLOOD

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

(2011) Y. Shen et al.   BLOOD

Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups

(2011) S C Lück et al.   LEUKEMIA

Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia

(2011) Sang Hyuk Park et al.   LEUKEMIA RESEARCH

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

(2010) J. A. Pollard et al.   BLOOD

KITmutations confer a distinct gene expression signature in core binding factor leukaemia

(2010) Sonja C. Lück et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid Leukemia

(2010) Andrea Corbacioglu et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience

(2010) R Guièze et al.   LEUKEMIA

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?

(2009) Hervé Dombret et al.   CURRENT OPINION IN HEMATOLOGY

Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact ofC-KIT,FLT3, andJAK2mutations on clinical outcome

(2009) Jana Marková et al.   LEUKEMIA & LYMPHOMA

Core Binding Factor Acute Myeloid Leukemia

(2008) Peter Paschka   SEMINARS IN ONCOLOGY